Drugs / LEO 27847
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01143298 | Jun → Aug 2010 | — | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01141179 | May 2010 → Feb 2011 | impaired renal function disease | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01007383 | Sep 2009 → Mar 2010 | — | LEO Pharma | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01167309 Comparator | Jun 2010 → Oct 2011 | secondary hyperparathyroidism of renal origin | LEO Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEO 27847 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01167309 ↗ |
| Route | Oral | “A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects” NCT01007383 ↗ |